Group 1 - The controlling shareholder of Tonghua Dongbao Pharmaceutical Co., Ltd., Dongbao Industrial Group, and its concerted parties hold approximately 641 million shares, accounting for 32.75% of the company's total shares [1] - The total number of shares pledged by Dongbao Group and its concerted parties is approximately 562 million shares, which represents 87.69% of their total holdings and 28.72% of the company's total shares [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或者重大 遗漏。 惠州中京电子科技股份有限公司（以下简称"公司"）于近日收到控股股东惠州市京港投资发展有限公司 （以下简称"京港投资"）发来的告知函。根据函件，京港投资向中国银河证券股份有限公司质押1300万 股，具体情况如下： 一、股份质押情况 3、公司控股股东及实际控制人不存在非经营性资金占用、违规担保等侵害上市公司利益的情形。 4、截至本公告披露日，控股股东京港投资及实际控制人杨林具备履约能力，上述质押股份行为不会导 致控制权的变更，所质押的股份不存在平仓风险或被强制平仓的情形，不会对上市公司生产经营、公司 治理产生不利影响。 5、公司将持续关注股东质押情况及质押风险情况，并按规定及时做好相关信息披露工作，敬请投资者 注意投资风险。 ■ 四、其他说明 1、公司控股股东及实际控制人上述质押主要用于其运营发展需要。 2、公司控股股东及实际控制人未来半年内到期的质押股份累计0股；未来一年内到期的质押股份累计 2,715万股，占其所持股份的17.50%，占公司总股本4.43%。还款 ...

Core Viewpoint - The announcement reveals that the controlling shareholder, Harmony Hengyuan, has pledged 12.6673 million shares to Guojin Securities Asset Management Co., Ltd., which accounts for 3.25% of its holdings and 1.66% of the total share capital, for debt repayment purposes [1] Group 1 - The pledge period is from January 5, 2026, to December 18, 2026 [1] - Harmony Hengyuan has also released a pledge of 14.03 million shares, representing 3.60% of its holdings and 1.84% of the total share capital [1] - As of the announcement date, Harmony Hengyuan holds 26.52% of the company's shares, and together with its concerted parties, the total holding is 50.98% [1] Group 2 - The cumulative pledged shares by Harmony Hengyuan account for 14.67% of the total share capital [1]

ST凯利公告，公司持股5%以上股东上海欣诚意投资有限公司及其一致行动人袁征分别于2025年12月31 日、2026年1月5日将所持3696.81万股、862.61万股办理质押，占各自所持股份100%，分别占公司总股 本5.16%、1.20%。质权人均为上海银行股份有限公司浦东分行，质押到期日均为申请解除质押登记 日，质押用途为合同履约担保。本次合计质押4559.42万股，占公司总股本6.36%。截至公告披露日，上 述股份不存在冻结、拍卖或设定信托情况。 ...

福鞍股份公告称，近日，控股股东福鞍控股办理了820万股股份质押及847万股股份解质押手续。截至公 告披露日，福鞍控股及其一致行动人持股1.72亿股，占总股本53.81%，累计质押1.30亿股，占其持股 75.17%，占总股本40.45%。本次质押分别为向王祎质押320万股、向重庆市万盛区恒辉小额贷款有限公 司质押500万股，均用于补充流动资金；解质押于1月5日完成。未来半年和一年内到期质押股份有明确 用途和还款资金来源，质押风险可控，不影响公司控制权等。 ...

合盛硅业公告称，近日接到控股股东合盛集团及其一致行动人罗立国部分股份质押及解质押通知。合盛 集团于12月22日质押90万股，占其所持股份0.18%，融资用于生产经营；12月26日，合盛集团、罗立国 分别解质960万股、640万股，占其所持股份1.97%、60.61%。截至公告日，合盛集团及其一致行动人合 计持股占总股本73.52%，累计质押股份4.18亿股，占其持股48.11%、总股本35.37%。质押风险可控，若 预警将采取措施应对。 ...

Group 1 - The core point of the announcement is that the controlling shareholder, Shuangliang Group, and its concerted actors have engaged in the pledge and release of shares, with specific details on the number of shares involved and their respective percentages of the total share capital [2][3][6] - As of December 19, 2025, Shanghai Tongsheng holds 319,222,403 shares, representing 17.04% of the total share capital, and has pledged 84,000,000 shares, which is 26.31% of its holdings and 4.48% of the total share capital [2] - Shuangliang Group holds 329,370,517 shares, accounting for 17.58% of the total share capital, and has pledged 230,000,000 shares, which is 69.83% of its holdings and 12.27% of the total share capital [2] Group 2 - The total shares held by Shuangliang Group and its concerted actors amount to 860,655,852 shares, representing 45.93% of the total share capital, with a cumulative pledge of 314,000,000 shares, which is 36.48% of their holdings and 16.76% of the total share capital [3][4] - The announcement indicates that the pledged shares are not used as collateral for major asset restructuring or performance compensation, and there are no potential performance compensation obligations associated with these shares [4][5] - The credit status of Shuangliang Group and Shanghai Tongsheng is reported to be good, indicating a controllable pledge risk [6] Group 3 - The company has announced a change in accounting estimates regarding the provision for bad debts, which will be applied prospectively without retrospective adjustment, starting from the date of the announcement [9][10] - The change in accounting estimates was approved by the company's board and audit committee, and it is stated that this change will not affect the financial status and operating results of the company in previous years [9][10] - The new accounting estimate involves conducting impairment tests on receivables from related parties, rather than using an aging analysis method, to provide a more accurate reflection of the company's financial status [12][13]

Group 1 - The core point of the article is that Shuangliang Energy has announced significant share pledges by its controlling shareholder, Shuangliang Group, which holds approximately 17.58% of the company's total shares [1] - As of now, Shuangliang Group has pledged 23 million shares, which accounts for 69.83% of its holdings and 12.27% of the total shares of the company [1] - The total shares held by Shuangliang Group and its concerted parties amount to approximately 861 million shares, representing 45.93% of the company [1] Group 2 - After the share pledges, the total pledged shares by the controlling shareholder and its concerted parties reached 31.4 million shares, which is 36.48% of their total holdings and 16.76% of the company's total shares [1] - For the first half of 2025, Shuangliang Energy's revenue composition is projected to be 68.99% from photovoltaic new energy and 31.13% from energy-saving and water-saving sectors, with inter-segment offsets at -0.12% [1] - The current market capitalization of Shuangliang Energy is 10.8 billion yuan [1]

Core Viewpoint - The announcement details the release and re-pledging of shares by the controlling shareholder, Fujian Taisheng Industrial Co., Ltd., indicating a stable financial situation and no adverse impact on the company's operations or governance [2][5][7]. Group 1: Shareholding and Pledge Details - As of the announcement date, the controlling shareholder and its concerted parties hold a total of 1,636,123,165 shares, accounting for 25.94% of the total share capital as of December 12, 2025 [2]. - The total number of pledged shares after the release and re-pledging is 782,079,602 shares, which represents 47.80% of the shares held by the controlling shareholder and its concerted parties, and 12.40% of the total share capital [2]. - The company received notification that the controlling shareholder will release and re-pledge 42,600,000 shares, which are unrestricted circulating shares [2][5]. Group 2: Future Pledge and Financial Stability - In the next six months, a total of 42,699,960 shares will mature, representing 26.10% of the controlling shareholder's total holdings and 6.77% of the company's total share capital, with a corresponding financing balance of 32,947,330 yuan [5]. - For the period of six months to one year, 19,498,000 shares will mature, accounting for 11.92% of the controlling shareholder's total holdings and 3.09% of the company's total share capital, with a financing balance of 15,888,000 yuan [5]. - The re-pledging of shares is primarily to secure financing for a designated trading enterprise, indicating that the controlling shareholder's financial situation is stable and there is no risk of default [5][7]. Group 3: Impact on Company Operations - The pledged shares will not be used as collateral for major asset restructuring or performance compensation [3]. - There are no indications of non-operational fund occupation, illegal guarantees, or related party transactions that could harm the company's interests [7]. - The current pledge risks are controllable, and there is no risk of forced liquidation or transfer of control over the company [7].

Core Viewpoint - The announcement reveals that the controlling shareholder, Lao Bai Xi Medicine Group, has pledged 14 million shares of Lao Bai Xi Pharmacy, which raises concerns about the company's financial stability and stock performance [1] Share Pledge Situation - The total number of shares pledged by the controlling shareholder amounts to 114 million, representing 63.25% of their holdings and 15.04% of the company's total share capital [1][2] - The pledge is intended to meet the operational needs of the medicine group, which claims to have the ability to repay the funds, with repayment sources including dividends from the listed company and self-raised funds [2][3] Future Pledge and Reduction Plans - In the next six months, 12.35 million shares are set to mature, accounting for 6.84% of the controlling shareholder's holdings and 1.63% of the company's total shares, with a corresponding financing amount of 100 million [3] - The medicine group plans to reduce its holdings by 18.11 million shares between June 20 and July 30, 2025, at a price range of 17.60 to 21.55 yuan per share, totaling approximately 341 million [4] Financial Performance - Recent financial results show that the company experienced a revenue decline of 0.36% year-on-year in 2024, with a net profit drop of 44.13% [5] - For the first three quarters of 2025, both revenue and net profit continued to decline, with decreases of 1% and 16.11%, respectively [5] - The company's stock price has fallen over 70% from its peak of 53.14 yuan per share in 2020, closing at 15.26 yuan per share with a total market capitalization of 11.58 billion [5]